1010
Naina Mishra
Chandigarh, June 5
A twofold rise in mucormycosis has been found in the first evidence-based multicentre study on Covid-19 Associated Mucormycosis (CAM) held in India between September and December last year, as compared to the same period in 2019.
The study which took place in 16 centres of India, including PGIMER, Chandigarh, compared epidemiology and outcomes among cases of coronavirus disease (Covid-19)–associated mucormycosis (CAM).
Under the doctors at PGIMER, a study was conducted with the name of MucoCovi (Muco from mucormycosis, Covi from Covid-19) study at 16 centres across the country. The study results were published yesterday in the reputed Emerging Infectious Disease Journal (Journal of CDC, Atlanta, USA) as ‘Multicenter Epidemiologic Study of Coronavirus Disease associated Mucormycosis, India’.